论文部分内容阅读
纳入52例LDL-C水平增高且血压控制良好的糖尿病肾病患者,随机分为瑞舒伐他汀组(n=26)和对照组(n=26)。通过监测治疗前和治疗后6个月时的血脂、高敏C-反应蛋白、尿白蛋白和半胱氨酸蛋白酶抑制剂C水平评估瑞舒伐他汀的效果。结果瑞舒伐他汀治疗能够有效地降低总胆固醇、LDL-C和三酰甘油水平,而对照组的血脂指标均未发生变化。虽然瑞舒伐他汀组的估算肾小球滤过率无明显改变,但半胱氨酸蛋白酶抑制剂C水平、尿液白蛋白排泄率和hs-CRP水平均显著性降低。多变量线性回归分析显示,瑞舒伐他汀治疗是尿白蛋白减少的独立影响因素(R2=0.53,P<0.001)。结论瑞舒伐他汀治疗能够降低糖尿病肾病患者的血脂水平并有可能改善肾功能。
Fifty-two patients with diabetic nephropathy with elevated LDL-C levels and good blood pressure control were randomized into rosuvastatin group (n = 26) and control group (n = 26). The effect of rosuvastatin was evaluated by monitoring the levels of blood lipids, high-sensitivity C-reactive protein, urinary albumin and cystatin C before and after 6 months of treatment. Results Rosuvastatin treatment can effectively reduce the total cholesterol, LDL-C and triglyceride levels, while the control group did not change the blood lipid indicators. Although estimated glomerular filtration rate did not change significantly in the rosuvastatin group, C levels, urinary albumin excretion rates, and hs-CRP levels were significantly lower. Multivariate linear regression analysis showed that rosuvastatin treatment was an independent predictor of urinary albumin reduction (R2 = 0.53, P <0.001). Conclusion Rosuvastatin can reduce the level of blood lipid in patients with diabetic nephropathy and may improve renal function.